FORTRESS BIOTECH, INC.

Profile

Company Names

FORTRESS BIOTECH, INC.
CORONADO BIOSCIENCES INC

Addresses

2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY 10014

45 ROCKEFELLER PLAZA, SUITE 2000, NEW YORK, NY 10111

1700 SEVENTH AVENUE, SUITE 2100, SEATTLE, WA 98101

Phone Numbers

781-652-4500
212-332-1665
206-826-7168

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, PHARMACEUTICALS

Year Incorporated:

2006

State Incorporated:

DELAWARE

Total Amount Raised:

$61,904,042.00

Number of Funding Rounds:

9
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
9
2018-02-28 
$6,517,000.00 
$30,000,000.00 
$23,483,000.00 
Debt 
8
2017-03-31 
$3,254,000.00 
INDEFINITE 
INDEFINITE 
Debt 
7
2011-05-31 
$25,784,568.00 
$28,765,040.00 
$2,980,472.00 
Equity 
6
2011-03-15 
$0.00 
$82,200.00 
$82,200.00 
 
5
2011-02-03 
$0.00 
$68,500.00 
$68,500.00 
 
4
2011-01-07 
$14,118,534.00 
$14,118,534.00 
$0.00 
Equity 
3
2010-05-28 
$3,989,940.00 
$27,499,987.00 
$23,510,047.00 
Equity 
2
2010-04-26 
$7,000,000.00 
$7,700,002.00 
$700,002.00 
Equity 
1
2009-07-27 
$1,240,000.00 
$3,500,000.00 
$2,260,000.00 
Debt 
People
First Name
Middle Name
Last Name
Titles
Related Companies
GEORGE 
 
AVGERINOS 
EXECUTIVE OFFICER
DAVID 
J. 
BARRETT 
DIRECTOR
GLENN 
L. 
COOPER 
DIRECTOR, EXECUTIVE OFFICER
GARY 
 
GEMIGNANI 
EXECUTIVE OFFICER
JIMMIE 
 
HARVEY 
DIRECTOR
JIMMIE 
 
HARVEY, JR. 
DIRECTOR
TIMOTHY 
M. 
HILLMAN 
EXECUTIVE OFFICER
TIMOTHY 
M. 
HOFER 
EXECUTIVE OFFICER
ROBYN 
 
HUNTER 
EXECUTIVE OFFICER
DOV 
 
KLEIN 
DIRECTOR
BERTRAND 
 
LIANG 
DIRECTOR
LUCY 
 
LU 
EXECUTIVE OFFICER
ELIZABETH 
 
MOORE 
EXECUTIVE OFFICER
STEPHEN 
 
PILATZKE 
EXECUTIVE OFFICER
DALE 
 
RITTER 
EXECUTIVE OFFICER
LINDA 
 
ROGERS 
EXECUTIVE OFFICER
MICHAEL 
W. 
ROGERS 
DIRECTOR
ERIC 
K. 
ROWINSKY 
DIRECTOR
BOBBY 
W. 
SANDAGE 
EXECUTIVE OFFICER, DIRECTOR
RAYMOND 
J. 
TESI 
EXECUTIVE OFFICER, DIRECTOR
PEGGY 
 
WENTWORTH 
EXECUTIVE OFFICER
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2018-02-28 
D
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2017-03-31 
D/A
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2011-05-31 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2011-05-31 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2011-03-15 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
 
2011-02-03 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2011-01-07 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2010-05-28 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Equity 
2010-04-26 
D
PHARMACEUTICALS 
 
DECLINE TO DISCLOSE 
Debt 
2009-07-27 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NATIONAL SECURITIES CORPORATION
NATIONAL SECURITIES CORPORATION
NATIONAL SECURITIES CORPORATION
NATIONAL SECURITIES CORPORATION
NONE
NONE
NATIONAL SECURITIES CORPORATION
NONE
NONE
PARAMOUNT BIOCAPITAL, INC.